Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) (Benzinga)
Tetraphase Pharmaceuticals Inc’s Ignite3 trial evaluating the company’s lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial. At last check, the shares were plunging nearly 61 percent to $2.12. Ignite3 Fails to Ignite Shares: The Ignite3 trial evaluated the efficacy and safety of once-daily intravenous eravacycline compared to ertapenem for treating patients with cUTIs. The trial did not achieve statistical non-inferiority of eravacycline to ertapenem, the company said in a release.
Twilio Inc (NYSE:TWLO) (The Motley Fool)
What happened: Shares of Twilio (NYSE:TWLO) soared on Wednesday morning following the release of strong fourth-quarter results. As of 11:40 a.m. EST, the digital communications specialist’s stock was trading 20.3% higher for the day. So what: Twilio’s total fourth-quarter sales rose 40% year over year to land at $115.2 million. The bottom line moved from a breakeven result in the year-ago quarter to an adjusted net loss of $0.03 per share this time.
Genesco Inc. (NYSE:GCO) (MarketWatch)
Genesco Inc. GCO, +11.19% shares surged 9.2% in Wednesday trading after the company announced plans to sell the Lids Sports Group business. Genesco’s board determined after a strategic review that it should focus on footwear while Lids specializes in hats and team sports fan shops. Genesco sells wholesale footwear through the Johnston & Murphy and Trask brands and licenses shoes from other brands. Nashville-based Genesco has more than 2,725 retail stores and leased departments in the U.S., Canada, the U.K., Ireland and Germany under the names Journeys, Lids, and other chains.
Nektar Therapeutics (NASDAQ:NKTR) (TheStreet)
Shares of Nektar Therapeutics (NKTR) soared in early trading on Wednesday, Feb. 14, after the San Francisco biotechnology company unveiled a collaboration agreement with Bristol-Myers Squibb Co. (BMY) for Nektar’s lead immuno-oncology program, NKTR-214. Nektar’s stock was trading at $86.38 on Wednesday afternoon, up 14.2%. Shares of Bristol-Myers were trading at $64.59, up 1.1%. Word of the collaboration came after Bloomberg reported on Feb. 2 that Nektar was mulling options, including a potential sale. The report added that Nektar could also pursue partnerships and licensing deals.
Fossil Group Inc (NASDAQ:FOSL) (CNBC)
Shares of Fossil Group skyrocketed Wednesday morning, after the company reported earnings and sales that topped analysts’ estimates because of a surprise jump in demand for wearables. The stock rallied more than 60 percent in the first hour of trading. Earlier, shares had surged more than 80 percent during premarket hours. Same-store sales climbed 2 percent in the fourth quarter, Fossil said Tuesday, as the company rolled out new hybrid and display smartwatches across 14 brands. E-commerce sales were up 31 percent during the period.
Motus GI Holdings Inc. (NASDAQ:MOTS) (MarketWatch)
Shares of medical device company Motus GI Holdings MOTS, -6.60% fell about 8% in their trading debut Wednesday, after the company priced its initial public offering at the low end of its $5 to $7 range. The Israeli company sold 3.5 million shares to raise $18.5 million. The company was originally planning to offer 4.3 million shares but reduced the size of the deal ahead of pricing. Few companies have braved the IPO market this week, given the recent volatility and a traditional seasonal lull as financials are updated.
DBV Technologies SA – ADR (NASDAQ:DBVT) (Benzinga)
DBV Technologies SA – ADR shares jumped 25.2 percent to $26.11 after the company disclosed that the U.S. FDA has agreed that the available efficacy and safety data for Viaskin Peanut supports the submission of a BLA for the treatment of peanut allergy in children four to 11 years of age.
Chipotle Mexican Grill, Inc. (NYSE:CMG) (The Motley Fool)
What happened: Shares of Chipotle Mexican Grill, Inc. (NYSE:CMG) were heating up today after the addled burrito chain named a new CEO, tapping Brian Niccol, the CEO of Yum! Brands’ (NYSE:YUM) Taco Bell, to lead its turnaround. Investors overwhelmingly approved of the decision, sending the stock up 15% as of 11:43 a.m. EST.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) (Benzinga)
Galmed Pharmaceuticals Ltd shares tumbled 51.7 percent to $4.57 after the company disclosed that its top line data from the ARRIVE study did not meet its primary endpoint. Maxim Group downgraded Galmed Pharmaceuticals from Buy to Hold.
Home Depot Inc (NYSE:HD) (CNBC)
Home Depot shares have been on shaky ground this month, falling 9 percent. But, one technically minded trader says its foundation is still solid.”If we see another downdraft in the broad market that takes it down to the 200-day moving average, that could be a real good entry point to either add to old positions or add new positions,” Matt Maley, equity strategist at Miller Tabak, told CNBC’s “Trading Nation” on Tuesday. Home Depot’s 200-day moving average is $166.78, or 8 percent lower than its current price.